Biocon’s subsidiary -- Biocon Biologics has surpassed the milestone of supplying 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia’s Ministry of Health (MoH). This achievement reinforces Biocon Biologics’ long-standing commitment to advancing diabetes care and ensuring affordable access to insulin across the country.
Since entering the Malaysian market in 2016, Biocon Biologics has played a pivotal role in transforming diabetes management, and has supplied over 100 million cartridges of rh-insulin serving over 345,000 patients. Biocon Biologics’ public-private partnership with the Malaysian government exemplifies a successful model for building a resilient biotech ecosystem by driving innovation, developing local talent, enabling better patient outcomes and advancing insulin self-sufficiency in Malaysia.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
